| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLES |
B Ligand and Their Differential Expression in Bone and Thymus1
Department of Pathology and Immunology (T.I., M.U., K.H.), Aging and Developmental Science, Graduate School, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo 113-8519, Japan; and Department of Bacterial and Blood Products (M.K.), National Institute of Infections Diseases, Shinjuku-ku, Tokyo 162, Japan
Address all correspondence and requests for reprints to: Tohru Ikeda, Department of Pathology and Immunology, Aging and Developmental Science, Graduate School, Tokyo Medical and Dental University, 15-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan. E-mail: toru.pth2{at}med.tmd.ac.jp
The receptor activator of nuclear factor (NF)-
B ligand [RANKL; also
known as tumor necrosis factor-related activation-induced cytokine,
osteoprotegerin ligand, and osteoclast differentiation factor] is
known to bind with the receptor activator of NF-
B (RANK) and act not
only as a key factor for osteoclastogenesis but also as a regulator of
lymphocyte development. In this study, we found two additional isoforms
of RANKL. RANKL 2 has a shorter intracellular domain than the original
RANKL (RANKL 1), and RANKL 3 lacks a transmembrane domain and was
thought to act as a soluble form. In the bone marrow stromal cell line
ST2 and preosteoblastic cell line MC3T3-E1, all three RANKL isoforms
were detected, but the expression of RANKL 2 was preferentially
suppressed by treatment with 1
,25-dihydroxyvitamin D3
and dexamethasone. In young adult thymus,
CD4-CD8- double-negative cells were positive
for all three isoforms, CD4+CD8+
double-positive cells were positive for RANKL 1 and RANKL 3 but
negative for RANKL 2, and CD4+CD8- and
CD4-CD8+ single-positive cells were positive
for all three isoforms. Immunofluorescence analyses of NIH3T3 cells
transfected with each RANKL isoform indicated that the three RANKL
isoforms were translated, and RANKL 2 protein predominantly stayed in
the endoplasmic reticulum and Golgi networks. These results indicate
that there are three kinds of RANKL-RANK pathways. The presence of
multiple RANKL-RANK pathways suggests a more complicated RANKL-RANK
system for osteoclastogenesis or T cell differentiation than previously
thought.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |